AxoGen and Blueprint Medicines Help Opaleye Return 91% Over the Last Year
James A. Silverman founded Opaleye Management back in 1996 and it was formerly known as Risk/Reward Capital.
Hedge Fund - Opaleye Management
Get Email AlertsJames A. Silverman Bio, Returns, AUM, Net Worth
Manager biography is currently missing.
Fund Profile
Filing Period:
| Fund Name: | Opaleye Management |
| Manager | James A. Silverman |
| Portfolio Value | $680,802,000 |
| Change This QTR | +0.89% |
Top 13F Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Security | Ticker | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|---|
| 1. | OCUL | 6,480,000 | $106,337 | -1% | 15.61% | |
| 2. | CMRX | 4,490,000 | $43,284 | +14% | 6.35% | |
| 3. | Protara Therapeutics Inc | 2,558,472 | $40,270 | 5.91% | ||
| 4. | BBIO | 583,767 | $35,960 | NEW | 5.28% | |
| 5. | CDXS | 1,400,000 | $32,046 | 4.7% |
Latest 13D & 13G Filings
| Company | Symbol | Filed By | Filing Date | Filing |
|---|---|---|---|---|
| 2021-06-17 | ||||
| 2021-02-12 | ||||
| 2021-02-12 | ||||
| 2021-02-12 |
News, Interviews and Investor Letters
This Healthcare Fund Just Had A Huge Q3: Here’s How
The mainstream media likes taking shots at hedge funds because they are easy targets.
More Than 60% Returns For These Two Hedgies’ Favorite Health Care Picks
The health care sector has appreciated by nearly 30% over the past year. We decided to take a look at three companies that two health care-focused funds, namely James A.
